11:14 AM EDT, 09/09/2025 (MT Newswires) -- Net prices for weight-loss drugs produced by the likes of Novo Nordisk ( NVO ) and Eli Lilly ( LLY ) were seen as "cost-effective", said the Boston-based Institute for Clinical and Economic Review in a draft study on Tuesday.

The institute gave Novo's semaglutide and Eli Lilly's ( LLY ) tirzepatide high cost-effectiveness ratings and said these therapies resulted in increased quality-adjusted life-years and fewer cardiovascular events compared to treatment with lifestyle modifications alone.

Despite these obesity therapies being cost-effective, their potential budget impact is large, the research body said, adding that it estimated less than 1% of the eligible patients could be treated at current and assumed net prices before exceeding the budget impact modeled by the ICER in its study.

Shares of Novo Nordisk ( NVO ) were down nearly 2% while Eli Lilly's ( LLY ) stock was up 1.3% in recent Tuesday trading.

Price: 53.24, Change: -1.04, Percent Change: -1.91